Bachem Holding AG Class B (CH:BANB)
:BANB
Want to see CH:BANB full AI Analyst Report?
BANB Stock Chart & Stats
CHF70.15
CHF0.05(0.09%)
At close: 4:00 PM EST
CHF70.15
CHF0.05(0.09%)
Day’s Range― - ―
52-Week RangeCHF48.52 - CHF83.25
Previous CloseN/A
Volume38.68K
Average Volume (3M)109.83K
Market Cap
CHF4.95B
Enterprise ValueCHF5.79B
Total Cash (Recent Filing)CHF30.99M
Total Debt (Recent Filing)CHF57.39M
Price to Earnings (P/E)33.3
Beta0.76
Next Earnings
Jul 30, 2026EPS Estimate
0.41Next Dividend Ex-DateN/A
Dividend Yield1.43%
Share Statistics
EPS (TTM)1.99
Shares Outstanding75,000,000
10 Day Avg. Volume97,857
30 Day Avg. Volume109,830
Financial Highlights & Ratios
PEG Ratio1.27
Price to Book (P/B)3.08
Price to Sales (P/S)6.46
P/FCF Ratio-93.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF85.20Price Target Upside21.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)2.36
Revenue Forecast (FY)CHF948.52M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExtremely low leverage and a growing equity base give Bachem long-term financial resilience. This conservatism supports funding for capacity, honors long-term supply contracts, and cushions business cyclicality, preserving strategic optionality across 2–6 months and beyond.
Solid ProfitabilityConsistent revenue expansion and a roughly 21% net margin indicate durable operating strength. Healthy margins support reinvestment in process development and quality systems essential for peptide CDMO work, sustaining competitive standing over coming quarters.
Recurring CDMO Commercial RevenueBachem's mix of commercial API supply under long-term contracts plus development-to-commercial CDMO services creates recurring, contractually anchored revenue. This business model yields multi-year visibility and high switching costs for customers, stabilizing mid-term cash flows.
Bears Say
Persistent Negative Free Cash FlowPersistent negative free cash flow despite positive operating cash suggests heavy capex or working-capital absorption. Over time this constrains balance-sheet flexibility and limits internally funded growth or returns unless investment yields clear commercial ramp-ups.
Step-up In Debt In 2025Although absolute leverage remains low, the 2025 increase in total debt marks a change in financing posture. If this trend continues to fund capacity or working capital, interest and covenant risk could rise, reducing the margin of safety from the previously ultra-conservative balance sheet.
Margin Drift & Pipeline RelianceGradual margin compression and dependence on projects advancing to commercial scale create structural timing and mix risk. If the project mix skews to lower-margin or commercial transitions delay, reported profitability and cash conversion could weaken over the medium term.
Bachem Holding AG News
BANB FAQ
What was Bachem Holding AG Class B’s price range in the past 12 months?
Bachem Holding AG Class B lowest stock price was CHF48.52 and its highest was CHF83.25 in the past 12 months.
What is Bachem Holding AG Class B’s market cap?
Bachem Holding AG Class B’s market cap is CHF4.95B.
When is Bachem Holding AG Class B’s upcoming earnings report date?
Bachem Holding AG Class B’s upcoming earnings report date is Jul 30, 2026 which is in 45 days.
How were Bachem Holding AG Class B’s earnings last quarter?
Bachem Holding AG Class B released its earnings results on Mar 12, 2026. The company reported CHF1.32 earnings per share for the quarter, beating the consensus estimate of CHF0.923 by CHF0.397.
Is Bachem Holding AG Class B overvalued?
According to Wall Street analysts Bachem Holding AG Class B’s price is currently Undervalued.
Does Bachem Holding AG Class B pay dividends?
Bachem Holding AG Class B pays a Annually dividend of CHF0.9 which represents an annual dividend yield of 1.43%. See more information on Bachem Holding AG Class B dividends here
What is Bachem Holding AG Class B’s EPS estimate?
Bachem Holding AG Class B’s EPS estimate is 0.41.
How many shares outstanding does Bachem Holding AG Class B have?
Bachem Holding AG Class B has 75,000,000 shares outstanding.
What happened to Bachem Holding AG Class B’s price movement after its last earnings report?
Bachem Holding AG Class B reported an EPS of CHF1.32 in its last earnings report, beating expectations of CHF0.923. Following the earnings report the stock price went up 7.734%.
Which hedge fund is a major shareholder of Bachem Holding AG Class B?
Currently, no hedge funds are holding shares in CH:BANB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bachem Holding AG Class B
Bachem Holding AG serves pharmaceutical and biotechnology companies globally, providing products crucial for research, clinical development, and commercial use. The company's primary focus is on the design, manufacturing, and regulatory support for peptide active pharmaceutical ingredients (APIs), specifically targeting novel peptide and oligonucleotide chemical entities (NCEs). Additionally, Bachem offers commercially available NCEs and generic compounds. Its comprehensive service portfolio includes project management, quality assurance and regulatory guidance, analytical testing, production adhering to Good Manufacturing Practices (GMP), manufacturing for research purposes, and expertise in supply chain and vertical integration. Established in 1971, Bachem Holding AG is headquartered in Bubendorf, Switzerland, and functions as a subsidiary of Ingro Finanz AG.
BANB Stock 12 Month Forecast
Average Price Target
CHF85.20
▲(21.45% Upside)
Technical Analysis
Lonza Group Ltd
―
Siegfried Holding AG
―
Ypsomed Holding AG
―
PolyPeptide Group AG
―
Galenica AG
―
Options Prices
Currently, No data available
---